Claims
- 1. A dihydropyridine compound of the formula ##STR149## or a pharmaceutically acceptable acid addition salt thereof, wherein R is phenyl; phenyl substituted by one or two of nitro, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, trifluoromethyl or cyano; 1-naphthyl; or 2-naphthyl;
- R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl;
- R.sup.3 is a 5-membered heterocyclic group derived from imidazole or imidazoline; or a mono- or di-substituted 5-membered heterocyclic group derived from imidazole or imidazoline wherein said substituent is independently selected from the group consisting of C.sub.1 -C.sub.4 alkyl, hydroxy, oxo, acetyl and gem-dimethyl; with the proviso that R.sup.3 is attached to the adjacent nitrogen atom by means of a bond between a carbon atom of R.sup.3 and the adjacent nitrogen atom; and
- Y is alkylene or alkylene substituted by 1 or 2 methyl groups wherein alkylene in each instance has 2-4 carbon atoms.
- 2. A compound according to claim 1 wherein R is 2-chlorophenyl, 2,3-dichlorophenyl or 2-chloro-3-(trifluoromethyl)-phenyl.
- 3. A compound according to claim 4 wherein Y is ethylene and R.sup.1 is methyl and R.sup.2 is ethyl or R.sup.1 is ethyl and R.sup.2 is methyl.
- 4. A compound according to claim 3 wherein R.sup.3 is ##STR150##
- 5. The compound of claim 4 wherein R is 2-chlorophenyl, R.sup.1 is methyl, R.sup.2 is ethyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-imidazol-2-yl.
- 6. The compound of claim 4, wherein R is 2-chlorophenyl, R.sup.1 is methyl, R.sup.2 is ethyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-5,5-dimethyl-imidazol-2-yl.
- 7. The compound of claim 4, wherein R is 2,3-dichlorophenyl, R.sup.1 is methyl, R.sup.2 is ethyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-imidazol-2-yl.
- 8. The compound of claim 4, wherein R is 2,3-dichlorophenyl, R.sup.1 is methyl, R.sup.2 is ethyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-5,5-dimethyl-imidazol-2-yl.
- 9. The compound of claim 4, wherein R is 2-chloro-3-trifluoromethylphenyl, R.sup.1 is methyl, R.sup.2 is ethyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-imidazol-2-yl.
- 10. The compound of claim 4, wherein R is 2,3-dichlorophenyl, R.sup.1 is ethyl, R.sup.2 is methyl, Y is ethylene and R.sup.3 is 3,4-dihydro-4-oxo-imidazol-2-yl.
- 11. A pharmaceutical composition comprising an antihypertensive, anti-schematic or angina-alleviating effective amount of a compound of claim 1 and a phramaceutically acceptable diluent or carrier.
- 12. A method of treating hypertension in an animal in need of such treatment comprising the step of administering to said animal an antihypertensive effective amount of a compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8236347 |
Dec 1982 |
GBX |
|
Parent Case Info
This is a divisional application of copending application Ser. No. 562,482, filed Dec. 16, 1983, now U.S. Pat. No. 4,572,908 issued Feb. 25, 1986.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4430333 |
Campbell et al. |
Feb 1984 |
|
4515799 |
Campbell et al. |
May 1985 |
|
4616024 |
Campbell et al. |
Oct 1986 |
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0031801 |
Jul 1981 |
EPX |
0060674 |
Sep 1982 |
EPX |
0089167 |
Sep 1983 |
EPX |
55-47656 |
Apr 1980 |
JPX |
1585978 |
Mar 1981 |
GBX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
562482 |
Dec 1983 |
|